Nov. 02, 2026 — Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), a leading cannabis company and agricultural markets platform, today announced that it has received registrations from the U.S. Drug Enforcement Administration (“DEA”) for all 41 of its state-licensed medical cannabis dispensaries in Florida.
Vireo’s registrations are among the initial federal registrations issued by the DEA to qualifying state-licensed medical marijuana dispensaries under the new Schedule III framework established by the DEA’s April 2026 final rule. The initial issuance represents an important regulatory milestone for Vireo’s Florida operations and the broader medical cannabis industry.
“Florida is one of our key markets, and we are pleased to have received these registrations,” said John Mazarakis, Chief Executive Officer of Vireo. “We appreciate the DEA’s efforts in advancing this process and welcome continued progress toward a federal regulatory framework that recognizes responsible, state-licensed cannabis operators and supports a more stable and sustainable industry.”
About Vireo Growth Inc.
Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) is a leading vertically integrated cannabis company building a broad platform across cannabis and adjacent agricultural markets. The Company operates cultivation, manufacturing, retail dispensaries, home delivery, distribution, and agricultural supply businesses across the United States, creating exposure to both cannabis and complementary adjacent markets. With operations in 10 states and approximately 180 operational dispensaries nationwide, Vireo combines disciplined capital allocation, strategic acquisitions, and local market execution to scale its platform and drive long-term shareholder value. The Company is focused on expanding market share and strengthening its portfolio of consumer brands and services, while supporting the customers, employees, shareholders, and communities it serves. For more information about Vireo, visit www.vireogrowth.com.
